Stephen Braye

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Giuseppe Viale, Meredith M. Regan, Eugenio Maiorano et al. · Journal of Clinical Oncology · 2007 · 452 citations · Full text

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

Giuseppe Viale, Anita Giobbie‐Hurder, Meredith M. Regan et al. · Journal of Clinical Oncology · 2008 · 340 citations · Full text

Re-evaluating Adjuvant Breast Cancer Trials: Assessing Hormone Receptor Status by Immunohistochemical Versus Extraction Assays

Meredith M. Regan, Giuseppe Viale, Mauro G. Mastropasqua et al. · JNCI Journal of the National Cancer Institute · 2006 · 167 citations · Full text

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Birgitte Rasmussen, Meredith M. Regan, Anne E. Lykkesfeldt et al. · The Lancet Oncology · 2007 · 151 citations

Supplementary Results, Endocrine Oncology, Breast Oncology +14

Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study Group

Giuseppe Viale, Meredith M. Regan, Eugenio Maiorano et al. · Journal of Clinical Oncology · 2008 · 115 citations · Full text